Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19976457 | 0.86 | ALDH1A1 (0.44) | ALDH1A1GAAMAPTL3MBTL1KDM4E | |
| SCHEMBL23011933 | 0.81 | ALDH1A1 (0.41) | ALDH1A1GAAMAPTL3MBTL1KDM4E | |
| SCHEMBL3078167 | 0.81 | ALDH1A1 (0.46) | ALDH1A1GAAMAPTL3MBTL1KDM4E | |
| SCHEMBL24973095 | 0.81 | KMT2A (0.41) | GAAMAPTLMNASMN1; SMN2 | |
| SCHEMBL8245704 | 0.80 | ALDH1A1 (0.47) | ALDH1A1GAAMAPTL3MBTL1KDM4E | |
| SCHEMBL3086043 | 0.79 | ALDH1A1 (0.41) | ALDH1A1GAAMAPTL3MBTL1KDM4E | |
| SCHEMBL24974211 | 0.79 | CYP11B1 (0.37) | — | |
| SCHEMBL18924321 | 0.79 | CPB2 (0.50) | — | |
| SCHEMBL24105600 | 0.78 | HRH3 (0.39) | ALDH1A1MAPTL3MBTL1KDM4ELMNA | |
| SCHEMBL20361778 | 0.77 | ALDH1A1 (0.43) | ALDH1A1GAAMAPTL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183015-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | LIPC, CPT1A, FABP1 | ALDH1A1 779/4885GAA 614/4885MAPT 4172/4885 |
| US-10183015-B2 | Heterocyclic compounds and methods of use | LIPC, CPT1A, FABP1 | ALDH1A1 779/4885GAA 614/4885MAPT 4172/4885 |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | HRAS, VHL, ESRRB | ALDH1A1 2384/4885GAA 1702/4885MAPT 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.